Skip to main content

Table 2 Effect of MEK162/BKM120 combination and BIBW2997/ARQ197 combination therapy on NSCLC H1975, H460, and A549 cell cycle distribution

From: Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds

Group Cell cycle distribution (%)
G0/G1 S G2/M
H1975 cells    
Control 61.5 + 3.6 29.4 + 2.3 9.1 + 6.3
BKM120 + MEK162 81.3 + 2.7* 12.9 + 6.5 5.8 + 2.2
BIBW2992 + ARQ197 92.6 + 5.5*# 3.5 + 2.4 3.9 + 1.4
H460 cells    
Control 58.4 + 6.6 24.4 + 8.3 17.2 + 7.3
BKM120 + MEK162 90.5 + 3.8* 6.1 + 5.2 3.4 + 3.2
BIBW2992 + ARQ197 59.5 + 5.6#▲ 22.7 + 3.4 17.8 + 7.4
A549 cells    
Control 63.1 + 9.1 25.7 + 6.3 11.2 + 4.3
BKM120 + MEK162 85.3 + 7.6*& 8.8 + 2.5 5.9 + 3.8
BIBW2992 + ARQ197 61.4 + 5.5#▲ 27.1 + 6.4 11.5 + 6.4
  1. H1975, H460, and A549 cells were treated with 1 μM MEK162/5 μM BKM120 combination and 1 µM BIBW2992 (EGFR inhibitor)/2 µM ARQ 197 (MET inhibitor) combination for 48 h. Control cells were treated with 0.05% DMSO. Each value represents mean ± SD obtained from three independent experiments
  2. *P < 0.05 vs. Control; #P < 0.05 vs. BKM120 + MEK162; P < 0.05 vs. H1975 cells; &P < 0.05 vs. H460 cells under the same cell cycle phase and the same drug treatment